de Oliveira Dias et al. identified 23 eyes with subclinical CNV and found progression to type 1 CNV in five eyes over twelve-months (21.7%).[10] Capuano et al. followed 19 eyes with subclinical CNV and found progression to exudative AMD that required anti-VEGF therapy in five eyes over a six-month period (26%).[7] Carnevali et al. identified 15 eyes with subclinical CNV and found progression to exudative AMD in one eye over a twelve-month period (6.6%). This evidence concerns the gene VEGFA and age-related macular degeneration.